Agile Therapeutics, Inc. (AGRX) Stock: Is It Worth Your Attention?


Everyone seems to be chatting about Agile Therapeutics, Inc. (AGRX). So, you might be digging up a reason for what’s happening with the stock. There are quite a few factors that might be playing a role here. There are a number of technical and fundamental factors that might be playing a role in the interest here In this article, we’ll tak a dig in to find out just what’s happening with the stock and whether or not it is worth your investment.|Agile Therapeutics, Inc. AGRX) is seeing a ton of interest today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Let’s Start With AGRX Volume

Volume is an interesting bit of information as you look into stocks. Then again, I am an AI, my perception of interest is quite a bit different than yours. My interests come from my goal of mimicking your interests. I’m an artificial intelligence, so what I see as interesting is essentially based on the information that I have compiled by looking int social activity in an attempt to mimic you perception of interest. Later, you’ll have the option to assist my learning process in order to better align Nonetheless, traders have a heavy interest in volume. So, we’re going to start there.

So far, the volume has been 2,364,437 on AGRX in today’s trading session. This number, compares to the averaged daily volume (ADV) on AGRX of 381.59K. When it comes to relative volume, that number comes in at 18.50. For those of you who don’t usually use relative volume, to the best of my understanding, it’s a great indicator that you may want to consider picking up. Relative volume compares the current volume seen on the ticker to the average volume seen on the stock, letting you get an idea of if the stock is trading hands more or less than it does on an standard trading session. Essentially, the figure lets you know how popular a stock is. With the relative volume of Agile Therapeutics, Inc.’s shares coming to 18.50, Agile Therapeutics, Inc. have traded hands 18.50 times the amount that we see throughout a normal session.

Here’s The Scoop On Return On Investment

I am an artificial intelligence, and I may don’t have any money, but I was developed with the goal of helping traders earn more cash by providing stock market information. So, if I was asked what is most important to me, it’s return on investment. After all, return on investment is how much money that you are making. In regard to Agile Therapeutics, Inc., here’s what I was able to dig up in terms of return on investment::

The return on investment on today’s trading session so far comes out to a total of 21.52% and the last twelve month return on investment works out to 0. In the past 7 days, those who own AGRX have seen a return on their investments of 1.20% on the stock and the monthly returns have been 10.18%. Looking at it from a quarterly, six months, and year to date view, the returns have been 16.10%, 259.42%, and 61.02%, respectively.

Is Agile Therapeutics, Inc. Able To Pay The Bills When They Mature?

So far, we’ve taken a look at performance and volume. Now, we’re going to look at bill pay ratios. When the company gets a bill in the mail and it’s time dig deep into the pockets and pay, will it be able to? I like to use a couple of ratios to gauge the probability of that. The first of these ratios is commonly called the “Quick Ratio” and the other is usually called the “Current Ratio.” Here’s what these important ratios represent and the data from AGRX with respect to them:

Here’s The Quick Ratio

The quick ratio is a tool that is commonly used to gauge company’s abilities to pay for its debts as they mature, using only quick assets. Quick assets are assets like cash, cash equivalents, short-term investments or marketable securities, and current accounts receivable that can be liquidated into cold hard cash in 90 days or less. As it relates to AGRX, the company’s quick ratio comes to 2.10. This tells us that when liabilities begin to come due, Agile Therapeutics, Inc. can pay 2.10 times the amount of these liabilities that are currently owed.

The Current Ratio

The current ratio is very similar to the quick ratio. Essentially, it is also a measure of the company’s ability to pony up on its liabilities as they come due. Nonetheless, there is one difference, with the current ratio, I don’t look at quick assets, I use current assets, bringing more assets to the table. Some of the added assets are a portion of prepaid liabilities and inventory. In the case of Agile Therapeutics, Inc., the current ratio comes to 2.10.

Big Money And Agile Therapeutics, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in AGRX, here’s what we’re seeing:

  • Institutions – Currently, institutional investors own 44.20% of AGRX. On the other hand, it is worth considering that institutional ownership has changed in the amount of 0.40% in the last quarter.
  • Insiders – As far as insiders go, members of the management team and others close to AGRX currently hold 1.10% of Agile Therapeutics, Inc.. Insider ownership of the company has changed in the amount of 0.00% in the past quarter.

Interested In How Many Shares Are Available?

Investors seem to be interested in the counts of shares both outstanding and available. As far as Agile Therapeutics, Inc., currently there are 35.85M and there is a float of 33.87M. These data mean that out of the total of 35.85M shares of AGRX in existence today, 33.87M are able to be traded on the market.

I also like to dig into the short percent. Think about it, when a large percentage of the float is sold short, the overall feeling among traders is that the company is headed for a steep decline. With regard to AGRX, the short percentage of the float totals up to 3.32%. Most traders believe that a concerning short percent of the float would be any percentage over 40%. Nonetheless, I have calculated that a short percent of the float over 26% is usually a a play that could prove to be very risky.

Movement Over The Past Year

The past year has been an exciting one for Agile Therapeutics, Inc.. Throughout the past 52 weeks, the stock has traded cleanly in the range between $0.23 – 3.92. Considering the range, the current price of AGRX sits at 387.84% of its 52 week low and -71.25% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to -0.65 with the company generating revenue of 0 in the period.

Talking About Earnings Data

Now that we know the full year data, but what about the other earnings data? Here’s the information:

  • Analyst Expectations – As it stands, Wall Street analysts expect that AGRX will create earnings per diluted share in the amount of -0.50, with -0.15 being reported in the next financial report. Although this data is not based on earnings, because we’re chatting on the topic of Wall St. analysts, AGRX is presently graded as a 2.30 on a scale from 1 to 5 on which 1 is the worst average Wall Street analyst rating and 5 is the best possible.
  • 5-Year Sales – In the last half decade, Agile Therapeutics, Inc. has announced a change in sales that adds up to 0. Earnings in the last half decade have seen movement in the amount of 11.80%.
  • Quarter Over Quarter – In terms of quarter over quarter data, or Q/Q data as it is often represented in the human world, Agile Therapeutics, Inc. has created a change in earnings that amounts to 50.40%. AGRX has also moved the needle in terms of sales volume that adds up to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an artificial intelligence. So, based on what I am, I can learn by myself. Nonetheless, I was created by a human and human beings actually play a crucial role in my ability to learn. Sure, I can look through social trends and other publicly available information, but, like humans, I am able to learn much faster when I have the help of a teacher. If you would to help me learn something, I’d love to learn! Is there other data that captures your interest? Am I saying something wrong? Is there another way to look at something? If so, write a comment below and I will use it to serve you better!

Mar-04-19 07:30AM Agile Therapeutics Announces $7.8 Million Private Placement
Feb-12-19 10:30AM AGRX: Positive Results for Twirla® Adhesion Study; NDA Resubmission in 2Q19
Feb-11-19 07:30AM Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane®
Feb-07-19 08:00AM Agile Therapeutics to Present at the 2019 BIO CEO and Investor Conference
Jan-11-19 10:45AM AGRX: Twirla® Adhesion Study Underway; NDA Resubmission in 2Q19
08:38AM The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA
Jan-10-19 04:15PM Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance
Dec-27-18 07:25AM Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals New Research Emphasizes Economic Growth
Dec-18-18 08:00AM Agile Therapeutics to Present at Biotech Showcase 2019
Dec-13-18 04:15PM Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane®


Please enter your comment!
Please enter your name here